Background Preservation injury in the HCV liver transplant population has been reported to correlate with poorer survival outcomes compared to preservation injury in the non-HCV liver transplant population. However, determinants of progression to cirrhosis in HCV infection remain poorly defined in this population. Aim This study aimed to determine if the presence and severity of preservation injury impact the acceleration of HCV recurrence and survival after liver transplant.
Introduction
Hepatitis C (HCV) infection is a global burden with an estimated prevalence of 2 % in the United States [1, 2] . HCV-related end stage liver disease continues to be the leading cause of hepatocellular carcinoma (HCC) and the most common indication for liver transplantation (LT) [3] . A number of risk factors for recurrent HCV viremia post-LT have been described, including recipient age and race, pre-transplantation HCV-RNA levels, recipient warm ischemia time (WIT), diabetes, HLA haplotype, immunosuppressive regimens, cytomegalovirus infection, donor gender and age, and rejection [4] [5] [6] [7] [8] [9] [10] . Similarly, the occurrence of preservation injury (PI) in the HCV LT population has been reported to correlate with poorer survival outcomes compared to PI in the non-HCV LT population or HCV LT population without PI [11] . However, determinants of progression in this HCV population remain poorly defined. Therefore, the aim of this study was to determine if the presence and severity of PI impact the acceleration of HCV recurrence and survival after LT.
In the transplant setting, cold preservation, ischemia, and implantation and reperfusion of the allograft lead to the phenomenon of PI. PI can be suspected with postoperative elevation of hepatic transaminases. However, the diagnosis is confirmed based on histological findings of pyknosis, sinusoidal neutrophilia, microvesicular steatosis, and hepatocellular cytoaggregation; and late findings of centrilobular necrosis, hepatocyte swelling, and cholestasis [11] [12] [13] . After the widespread hepatocellular death associated with PI, hepatocyte proliferation occurs, and it has been hypothesized that HCV may be able to incorporate itself into these proliferating cells, which could then lead to more rapid HCV recurrence in the graft [11, [14] [15] [16] . PI has also been associated with increased patient mortality, delayed graft function, primary graft nonfunction, and late graft failure by triggering irreversible intrahepatic bile-duct injury or by promoting rejection graft failure, and post-LT biliary complications [11, [17] [18] [19] . In fact, the number of patients listed waiting for LT has dramatically increased leading to a high incentive to use extended criteria donor organs, which include organs with hepatic steatosis, old donor age, prolonged cold ischemia, or donation after cardiac death. Thus, these grafts are inevitably prone to a higher grade of PI.
Patients and Methods

Study Design and Study Population
We retrospectively reviewed and collected data on all LT performed at the University of Florida for HCV infection (424) between the years 1995 and 2005. Our study group consisted of 255 of these patients where post-transplant protocol biopsies (7-day, 4-month, and 1-year) were available for analysis. Biopsies from postoperative day (POD) 7 were mostly protocol biopsies. A few liver biopsies (18 %) on POD 7 later in our study were performed only for elevations in liver function tests due to a change in policy. The liver biopsies were reviewed by one, blinded hepato-pathologist.
The database also included variables that could potentially impact PI such as donor age, gender and ethnicity, recipient age, gender and ethnicity, ABO group, warm ischemia time and cold ischemia time (CIT), HCV genotype, exposure to interferon (IFN), and the presence of HCC. Laboratory data included peak liver transaminases, total bilirubin, alkaline phosphatase, c-glutamyl transpeptidase, and INR in the first postoperative week as well as the total bilirubin on the day prior to transplant. The study was approved by the institutional review board at the University of Florida.
Histology
Postoperative protocol biopsies at 7 days, 4 months, 1 year and annually thereafter were available as well as the final outcome of the subjects until the last clinic visit or death. After LT, we have defined two HCV patient populations; rapid fibrosers (RF) who have an accelerated rate of fibrosis of more than 0.8 Units/year, and slow fibrosers (SF) with a rate of fibrosis of less than 0.8 Units/year [20] . Patients with greater than 0.8 Units/year of fibrosis at their 4-month, 1-, or 2-year protocol biopsies were considered to be RF, and patients with less than 0.8 Units/year of fibrosis at their 4-month, 1-, or 2-year protocol biopsies were considered to be SF. Recurrent HCV disease was scored for inflammation and fibrosis, using the modified Knodell scoring system of Ishak et al. [21] . At present, since there is no clearly defined grading system for PI severity, a slightly modified scale from Killackey et al. was used to classify the specimens into four categories: negative, mild, moderate, or severe [22] . Injury was considered mild when the biopsy showed rare and scattered inflammatory cells in the lobule and minimal canalicular cholestasis. Moderate injury was considered when hepatocyte injury, consisting of feathery degeneration, necrosis, and/or drop out was present, but limited to zone 1 (periportal) area with increasing degrees of cholestasis and inflammation. Finally, injury was considered severe when the hepatocyte damage extended into zones 2 (located between the periportal and centrilobular areas) and 3 (centrilobular).
Immunosuppression
The immunosuppression consisted of cyclosporine in combination with prednisone ± Imuran prior to 1997. Tacrolimus became the primary calcineurin inhibitor for immunosuppression after 1997. The immunosuppression was tapered to tacrolimus or cyclosporine monotherapy within 4-6 months of LT. Sirolimus was used as part of a renal-sparing regimen as necessary when chronic renal insufficiency occurred during prolonged follow-up after transplantation. Combination therapy with IFN and ribavirin was initiated once patients developed significant fibrosis (Ishak fibrosis stage [2) on liver biopsy. The duration of treatment was 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3, if tolerated.
Statistical Analysis
The data were analyzed to see if there was an association with PI and accelerated HCV recurrence. Statistical analysis was also performed to see if an association of PI existed with any other variables recorded in the database using patients without PI in the study as the comparison group. Chi square test was used to compare categorical variables and Student's t tests were used to compare continuous variables. Survival time is defined as the time from the time of transplant to the date of death or the date of last 
Results
Patient Characteristics
A total of 932 adult LT were performed at the University of Florida from 1995 to 2005. Of the 424 patients that were transplanted for HCV, liver biopsies were available in 255 (60.1 %) patients. The mean age of the study group was 49.3 years, 180 (70.6 %) were male, and 221 (86.7 %) were Caucasian. The mean duration of post-transplant follow-up of the patients was 5.3 years. Pre-transplant IFN therapy was administered to 98 (38.4 %) patients and 132 (51.8 %) patients received post-transplant IFN therapy for HCV recurrence.
Preservation Injury
The incidence of PI as seen on the POD 7 liver biopsy was 69.0 % (n = 176). Among patients with PI, 48.3 % had mild injury, 44.9 % had moderate injury, and 6.8 % had severe injury. Table 1 compares donor and recipient demographic characteristics and transplant related data between patients with and without PI. Recipient and donor age, race, gender, or ABO group did not influence the occurrence of PI. Table 1 also compares liver function tests among patients with and without PI. The first postoperative week peak AST and ALT levels were found to be significantly greater in those with PI compared to patients without PI. When comparing all patients, patients that had 7-day liver biopsy with those who did not, they were very similar in most of the parameters except for CIT and donor gender. These characteristics were also compared between patients with different grades of PI severity as shown in Table 2 . Correlation between peak AST levels 1-week post LT and presence and severity of PI as diagnosed by 1 week biopsy was assessed. The Shackleton et al. classification was used to categorize AST values [23] . Overall, 75.4 % of patients with AST \ 600 IU; 81.9 % of patients with AST 600-2,000 IU and 97.1 % of patients with AST [ 2,000 IU showed presence of PI on biopsy (p = 0.008). Severity of PI was also found to correlate with peak AST levels (p \ 0.001). Thirty-six percent of patients with AST \ 600 IU; 47.7 % of patients with AST 600-2,000 IU and 79.4 % of patients with AST [ 2,000 IU demonstrated moderate-severe PI on biopsy.
Fibrosis
The association between occurrence of PI and prevalence of fibrosis progression was analyzed. The number of patients with available protocol biopsy data at 4 months, 1 and 2 years was 76.9 % (n = 196), 82.3 % (n = 210), and 72.5 % (n = 185), respectively. Figure 1 shows the comparison of prevalence of RF amongst patients with PI at 4 months, 1 and 2 years. The prevalence of RF was also compared between patients with different severities of PI and at 4 months, it was 55.1 % with mild PI and 48.4 % with moderate to severe PI (p = 0.277); at 1 year, it was 74.6 % among patients with mild PI and 78.2 % among patients with moderate to severe PI (p = 0.377); and at 2 years, it was 54.0 % among patients with mild PI and 60.9 % among patients with moderate to severe PI (p = 0.269).
Hepatitis Activity Index
The overall prevalence of advanced Hepatitis Activity Index (HAI) [4 at 1 year was 25.4 %. Among patients with PI the prevalence of advanced HAI at 1-year biopsy was 29.5 % and it was 15.6 % among patients without PI (p = 0.081). The prevalence of advanced HAI at 1 year was compared between patients with different grades of PI, and it was 32.7 % among patients with mild PI and 26.7 % among patients with moderate to severe PI (p = 0.286).
Survival
The median survival among patients with PI was 10.07 years, while it could not be reported in patients without PI as more than 50 % of the patients were alive at the end of the study period (Fig. 2a) . However, on comparison of the survival curves, no difference was found between patients with and without PI (p = 0.893). The severity of the PI also did not influence patient survival at 1, 3, and 5 years (Fig. 2b) . Five-year survival rates in patients with mild, moderate, and severe PI were 82, 83, and 92 %, respectively (p = 0.909). Post-transplant survival rates were compared between RF and SF (Fig. 2c) . Overall, 7.1 % of the cohort underwent re-transplantation for various indications, the major ones being hepatic artery thrombosis, recurrent hepatitis C, and primary non-function of the graft. We analyzed the impact of PI on allograft survival and did not find any difference in graft survival between patients with and without PI (0.897) (Fig. 2d) .
Discussion
In our study, the incidence of PI on POD 7 biopsy was found to be 69 %. Also, the presence of PI and the severity of PI were not associated with the development of rapid fibrosis in the HCV LT population up to 2 years after LT. The presence of PI did not affect patient or graft survival up to 5 years when compared to patients without PI. The severity of PI also did not influence patient survival up to 5 years after LT. Although the 5-year survival rates between RF and SF were not statistically significant, there was a trend towards improved survival with the SF. When compared to patients without PI, patients with PI had statistically significant higher peak AST, ALT, and INR laboratory values during the first week post-LT. There was also a statistically significant difference in GGT and CIT between patients with PI and without PI, and, interestingly, patients with PI were found to have shorter CIT and lower GGT levels.
Our results also show a higher percentage of PI after LT compared to other reported studies [12] . However, our results are similar to the study by Killackey et al. where a correlation could not be found between PI and the frequency and timing of histologic HCV recurrence. Their study also showed that the severity of PI did not impact patient survival [22] . However, protocol liver biopsies were not performed in this study. This is in contrast to the analysis performed by Watt et al. [11] . In their analysis, patients with HCV and any degree of PI were at an increased risk of death, and those with moderate to severe PI were at the highest risk. It was also suggested in their analysis that recurrent HCV disease appeared to be more rapidly progressive in patients with early PI on liver biopsy. Similar to the Killackey et al. study, protocol liver biopsies were not performed and therefore earlier recurrence of HCV in the setting of early PI could not be confirmed. Other variables such as donor age, moderate to severe macrovesicular steatosis, CIT, prolonged stay in the intensive care unit, peak hepatic transaminases post-LT, and high inotropic drug use have also been shown to be associated with PI [11, 22, 24] . In a previous study from our institution, WIT [60 min and older donor age were found to be associated with rapid fibrosis [20] . These two factors were not found to be different between patients with and without PI, hence eliminating any possible interference from these variables. However, as similarly shown by other studies, CIT does not always correlate with the severity of PI [22] . CIT has also been shown to not affect the severity of HCV post LT [25] . Though we cannot explain why the CIT was longer in patients without PI, this factor probably did not influence the outcome. Even though we had a large sample size, our study was mainly limited by its retrospective nature. Another limitation is the selection bias due to the lack of POD 7 liver protocol biopsies in every patient that was transplanted in our center. Only a small percentage of the patients Fig. 2 a The survival among patients with PI versus those without PI. PI preservation injury, No PI no evidence of preservation injury. b The survival rates at 1, 3, and 5 years among patients with PI were 98, 88, and 83 %, respectively, and among patients without PI they were 97, 94 and 79 % at 1, 3, and 5 years, respectively. PI preservation injury, No PI no evidence of preservation injury. c The survival rates at 1, 3, and 5 years in RF were 98, 89, and 80 %, and in SF they were 98, 94, and 91 % at 1, 3, and 5 years, respectively (p = 0.088). RF rapid fibrosis, SF slow fibrosis. d The impact of PI on allograft survival. As illustrated, we did not find any difference in graft survival between patients with and without PI. PI preservation injury, No PI no evidence of preservation injury (0.02 %) lost their graft prior to day 7, so we do not think that a statistical significant number of severe PIs were excluded from the study. Another subset of patients (18 %) underwent 7-day biopsy for abnormal LFTs and not as per protocol. However, in our study, the histopathologic findings correlated very well with the biochemical findings, so we think that only a small number of livers with PI were potentially excluded. Finally, another possible limitation is the long-term nature of the study. When we compared the incidence of PI before and after 2002, when pegylated interferon was introduced, we did not find a significant difference.
In conclusion, this large analysis of post-LT HCV patients showed that presence and severity of PI, defined by using POD 7 liver biopsies, were not associated with the development of rapid HCV recurrence. PI also did not impact 5-year patient or graft survival. Recurrence of HCV continues to remain a significant dilemma in the LT population particularly given the associated accelerated course and treatment difficulties. Further studies are needed in attempt to identify variables and risk factors in patients who develop rapid HCV recurrence after LT, since this could impact the initiation of antiviral therapy and subsequent patient and graft survival.
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